ArticleNature reviews. Clinical oncology2011
Challenges translating breast cancer gene signatures into the clinic.
Article in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Oncogene · 2016Trial
- Clinical significance of FOXN3 expression in Indian breast cancer patients.Scientific reports · 2025Article
- Best holdout assessment is sufficient for cancer transcriptomic model selection.Patterns (New York, N.Y.) · 2024Article
- THE SCALABLE BIRTH-DEATH MCMC ALGORITHM FOR MIXED GRAPHICAL MODEL LEARNING WITH APPLICATION TO GENOMIC DATA INTEGRATION.The annals of applied statistics · 2023Article
- Evaluating the role of MEN1 gene expression and its clinical significance in breast cancer patients.PloS one · 2023Article
- Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.British journal of cancer · 2021Article
- Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.BMC cancer · 2018Article
- An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.Frontiers in medicine · 2018Review
- Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.Breast cancer research : BCR · 2017Article
- Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures.International journal of genomics · 2017Article
- Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies.Cancer research · 2016Article
- Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.Oncotarget · 2016Article
- Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.Breast cancer research : BCR · 2016Article
- Chromatin Regulators as a Guide for Cancer Treatment Choice.Molecular cancer therapeutics · 2016Article
- General Assessment of Humoral Activity in Healthy Humans.Molecular & cellular proteomics : MCP · 2016Article
- Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.PloS one · 2016Article
- Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.PloS one · 2016Article
- Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.Oncotarget · 2015Article
- The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.Breast cancer research : BCR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The advent of microarray-based gene-expression profiling a decade ago raised high expectations for rapid advances in breast cancer classification, prognostication and prediction. Despite the development of molecular classifications, and prognostic and predictive gene-expression signatures, microarray-based studies have not yielded definitive answers to many of the questions that remain germane for the successful implementation of personalized medicine. There are a lack of robust signatures to predict benefit from specific therapeutic agents and it is still not possible to predict prognosis or chemotherapy treatment response in specific disease subsets accurately, such as triple-negative breast cancer. We discuss the hurdles in the development and validation of molecular classification systems, and prognostic and predictive signatures based on microarray gene-expression profiling. We suggest that similar challenges are likely to be encountered in translating next-generation sequencing data into clinically useful information. Finally we highlight strategies for the development of clinically useful molecular predictors in the future.
Indexed as
Identifiers
21878891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.